PHC Ventures Invests in Moonrise Medical to Advance Vascular Diagnostics and Limb-Saving Innovation 

Every day, patients lose limbs to preventable complications—often without ever receiving proper vascular testing. Now, a new partnership between Providence Health Care Ventures (PHC Ventures) and Moonrise Medical aims to change that reality. 

PHC Ventures has invested in a Canadian health technology startup developing an innovative ultrasound diagnostic tool to transform how vascular disease is diagnosed and treated—particularly for patients at risk of limb loss due to Peripheral Artery Disease (PAD) and diabetic foot ulcers. 

Across North America, hundreds of people lose limbs each year due to complications from PAD and diabetes. Many patients, especially those from marginalized communities, face delayed or inaccurate assessments due to outdated diagnostic tools and limited access to vascular specialists. Shockingly, a significant proportion of patients go straight to amputation without any prior vascular testing. For those who do lose limbs, the five-year mortality rate remains alarmingly high. 

This is exactly the problem Moonrise Medical has set out to solve. The company’s ultrasound-based device uses a specialized measurement technique called pedal acceleration time to assess blood flow in the lower limbs. This approach will forge a pathway to earlier, more accurate diagnosis and personalized treatment planning—without requiring a vascular specialist on site. 

The technology empowers nurses and technologists to perform comprehensive vascular assessments in minutes—diagnostics that were once the exclusive domain of highly trained experts. By automating complex assessments, it makes life-saving care accessible where it’s needed most. 

“We’re not just advancing technology—we’re democratizing access to critical vascular care,” said Adam Gold, CEO of Moonrise Medical. “Providence’s investment and clinical expertise will help us get this tool into the hands of frontline healthcare workers who can make the difference between saving a limb and losing it.” 

The investment will support Moonrise Medical as it moves from early clinical validation to commercial readiness and FDA approval. The company’s solution is uniquely positioned to improve patient outcomes by enabling timely interventions, reducing hospital stays, and increasing rates of limb preservation—all while lowering overall health care costs. 

For PHC Ventures, this partnership represents more than a promising investment. Moonrise’s technology complements the health system’s existing vascular services. By supporting Moonrise, PHC Ventures reinforces its commitment to improving care for the patients most at risk. 

“At PHC Ventures, we invest in technologies that not only promise clinical impact but also address deep inequities in access to care. Moonrise Medical’s innovation has the potential to fundamentally shift how vascular disease is diagnosed—especially for underserved patients who are too often overlooked. We’re proud to support a solution that brings limb-saving diagnostics to the front lines of care, where timing and access matter most.” 

— Brian Simmers, President, PHC Ventures 

This partnership marks a step forward in vascular care—bringing hope, precision, and equity to a field ready for innovation.